Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new national research project to study the effects of emerging mutations in SARS-CoV-2 will be launched with £2.5 million funding from UK Research and Innovation (UKRI).

Coronavirus © UKRI

The ‘G2P-UK’ National Virology Consortium* will study how mutations in the virus affect key outcomes such as:

  • how transmissible it is
  • the severity of COVID-19 it causes
  • the effectiveness of vaccines and treatments.

The Fodor Lab (Sir William Dunn School of Pathology) and the Grimes Lab (Nuffield Department of Medicine) are pleased to be part of this project through their collaboration on the SARS-CoV-2 RNA polymerase. Specifically, they will be addressing how emerging mutations in the SARS-CoV-2 replicase genes affect the ability of the virus to replicate its RNA genome and, in collaboration with the other partners in the consortium, how these changes impact the properties of the virus, such as transmissibility, severity of the disease it causes and the immune responses it triggers.

The full story is available on the UKRI website

Similar stories

Largest ever global study of tuberculosis identifies genetic causes of drug resistance

Using cutting-edge genomic sequencing techniques, researchers at the University of Oxford have identified almost all the genomic variation that gives people resistance to 13 of the most common tuberculosis (TB) drug treatments.

Peter Horby receives prestigious award for outstanding service to public health

The Faculty of Public Health (FPH) has awarded its prestigious Alwyn Smith Prize to Professor Sir Peter Horby (Nuffield Department of Medicine) for 2020/2021 in recognition of his outstanding service to public health as a global leader in epidemic science.

Six new Fellowships announced as part of Oxford-Bristol Myers Squibb Fellowships Programme

The Oxford - Bristol Myers Squibb (BMS) Fellowships Programme continued to demonstrate significant progress over the last year, despite the challenges associated with the global pandemic, including restricted lab access and work from home guidance. Today, we are pleased to announce six new Oxford-BMS Fellowships for 2021.

Researchers set out steps to address mental health effects of the pandemic on young people

Researchers have outlined 14 steps that schools, mental health services and policymakers can take to help children and young people whose mental health has been affected by the COVID-19 pandemic.

Anti-cancer drug derived from fungus shows promise in clinical trials

A new industry-academic partnership between the University of Oxford and biopharmaceutical company NuCana as found that chemotherapy drug NUC-7738, derived from a Himalayan fungus, has 40 times greater potency for killing cancer cells than its parent compound.

Professor Trish Greenhalgh Highly Commended in the O²RB Excellence in Impact Awards 2021

Congratulations to Professor Trish Greenhalgh (Nuffield Department of Primary Care Health Sciences) who has been Highly Commended in the O²RB Excellence in Impact Awards 2021.